XM does not provide services to residents of the United States of America.
B
B

BectonDickinson


News

U.S. STOCKS BorgWarner, Digital Realty, Take-Two

BUZZ-U.S. STOCKS ON THE MOVE-BorgWarner, Digital Realty, Take-Two Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes added to their gains on Thursday in the run-up to the Federal Reserve's interest-rate decision, extending a sharp rally sparked by Donald Trump's stunning comeback as U.S.
G
H
J
M
M
N
D
T
U
U
B
L
V
A
B
C
M

U.S. STOCKS Ralph Lauren, CoreCivic, WK Kellogg

BUZZ-U.S. STOCKS ON THE MOVE-Ralph Lauren, CoreCivic, WK Kellogg Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes held on to their gains on Thursday in the run-up to the Federal Reserve's interest-rate decision, extending a sharp rally sparked by Donald Trump's stunning comeback as U.S.
G
H
J
K
M
D
U
U
B
M
V
A
C
M

Becton Dickinson and Co reports results for the quarter ended in September 30 - Earnings Summary

Becton Dickinson and Co reports results for the quarter ended in September 30 - Earnings Summary Becton Dickinson and Co BDX.N reported quarterly adjusted earnings of $3.81​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $3.42. The mean expectation of fourteen analysts for the quarter was for earnings of $3.77 per share.
B

U.S. STOCKS Guardant Health, AppLovin, Sarepta

BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, AppLovin, Sarepta Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq were set to open higher in the run-up to an interest-rate decision from the Federal Reserve on Thursday, extending a sharp rally sparked by Donald Trump's stunning comeback as U.S.
G
H
J
M
U
U
B
V
A
C
M

BD Reports Fourth Quarter And Full Year Fiscal 2024 Financial Results

BRIEF-BD Reports Fourth Quarter And Full Year Fiscal 2024 Financial Results Nov 7 (Reuters) - Becton Dickinson and Co BDX.N : BD REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2024 FINANCIAL RESULTS BD - ISSUES FY25 REVENUE GUIDANCE INCLUDING GAAP GROWTH OF 8.9% TO 9.4%, ADJUSTED CURRENCY-NEUTRAL GROWTH OF 8.8% TO 9.3% BD OUTLOOK FY 2025 GAAP REVENUE
B

Becton Dickinson climbs after Q4 results beat

BUZZ-Becton Dickinson climbs after Q4 results beat ** Shares of medical device maker Becton Dickinson BDX.N rise ~2.5% to $246 premarket ** Co reports Q4 adj. profit of $3.81/shr vs analysts' average estimate of $3.77/shr - LSEG data ** Co's quarterly revenue of $5.44 billion beats analysts' average expectation of $5.38 billion ** Co forecasts annual adj.
B

Becton Dickinson beats quarterly estimates on strength in drug-delivery devices

Becton Dickinson beats quarterly estimates on strength in drug-delivery devices Nov 7 (Reuters) - Becton Dickinson BDX.N surpassed analysts' expectations for fourth-quarter results on Thursday, helped by strong demand for its drug-delivery devices. Medical technology firms such as Becton, Boston Scientific BSX.N and Abbott Laboratories ABT.N have been benefiting from robust demand for non-essential surgical procedures, especially among older patients.
A
B

Becton Dickinson Q4 Adjusted EPS USD 3.81 Vs. IBES Estimate USD 3.77

BRIEF-Becton Dickinson Q4 Adjusted EPS USD 3.81 Vs. IBES Estimate USD 3.77 Nov 07 (Reuters) - Becton Dickinson Q4 revenue USD 5,437 million. outlook FY adjusted EPS USD 14.25-14.6
B

BD Board Increases Dividend For 53rd Consecutive Year

BRIEF-BD Board Increases Dividend For 53rd Consecutive Year Nov 7 (Reuters) - Becton Dickinson and Co BDX.N : BD BOARD INCREASES DIVIDEND FOR 53RD CONSECUTIVE YEAR BECTON DICKINSON AND CO - DECLARES QUARTERLY DIVIDEND OF $1.04 PER SHARE Source text: ID:nPn2q2BGQa Further company coverage: BDX.N
B

What to Watch in the Day Ahead - Thursday, November 7

What to Watch in the Day Ahead - Thursday, November 7 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT The Federal Reserve is widely expected to slash its interest rate by 25 basis points following the conclusion of the two-day-long monetary policy meeting.
H
B
M

Becton Dickinson Says Commercial Launch Of First In Family Of High-Throughput, Robotics-Compatible Reagent Kits That Will Enable Automation

BRIEF-Becton Dickinson Says Commercial Launch Of First In Family Of High-Throughput, Robotics-Compatible Reagent Kits That Will Enable Automation Oct 14 (Reuters) - Becton Dickinson and Co BDX.N : BD: COMMERCIAL LAUNCH OF FIRST IN A FAMILY OF HIGH-THROUGHPUT, ROBOTICS-COMPATIBLE REAGENT KITS THAT WILL ENABLE AUTOMATION BD: BD OMICS-ONE XT LIBRARY P
B

Becton Dickinson agrees to settle about 38,000 hernia mesh suits

Becton Dickinson agrees to settle about 38,000 hernia mesh suits By Brendan Pierson Oct 3 (Reuters) - Becton Dickinson BDX.N has agreed to resolve nearly all U.S. lawsuits by people who say they were injured by its hernia repair mesh, about 38,000 cases, in an unusual settlement overseen jointly by state and federal courts, promising an end to litigation stretching back almost two decades.
B

Becton Dickinson And Co Reaches Agreement To Resolve Vast Majority Of Hernia Litigation

BRIEF-Becton Dickinson And Co Reaches Agreement To Resolve Vast Majority Of Hernia Litigation Oct 2 (Reuters) - Becton Dickinson and Co BDX.N : BD REACHES AGREEMENT TO RESOLVE VAST MAJORITY OF HERNIA LITIGATION BD - SETTLEMENT AMOUNT WITHIN CURRENT PRODUCT LITIGATION RESERVE AND WILL BE PAID OUT OVER A MULTI-YEAR PERIOD BD - SETTLEMENT WILL NOT CHA
B

Bd Completes Acquisition Of Critical Care From Edwards Lifesciences

BRIEF-Bd Completes Acquisition Of Critical Care From Edwards Lifesciences Sept 3 (Reuters) - Becton Dickinson and Co BDX.N : BD COMPLETES ACQUISITION OF CRITICAL CARE FROM EDWARDS LIFESCIENCES Source text for Eikon: ID:nPn70KdDva Further company coverage: BDX.N
B



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.